Acquisition by Forman Eric of 1112 shares of Lixte Biotechnology at 0.63 subject to Rule 16b-3
| LIXT Stock | USD 1.30 0.10 7.14% |
Slightly above 63% of Lixte Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Lixte Biotechnology Holdings suggests that many traders are alarmed. Lixte Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Lixte Biotechnology's earnings reports, geopolitical events, and overall market trends.
Lixte |
Filed transaction by Lixte Biotechnology Holdings Officer Vice President And Coo. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Lixte Biotechnology Fundamental Analysis
We analyze Lixte Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Lixte Biotechnology is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Lixte Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lixte Biotechnology stock to make a market-neutral strategy. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics with similar companies.
Peers
Lixte Biotechnology Related Equities
| SRRK | Scholar Rock | 7.95 | ||||
| INDP | Indaptus Therapeutics | 6.33 | ||||
| PASG | Passage Bio | 1.96 | ||||
| OLMA | Olema Pharmaceuticals | 0.91 | ||||
| ALLR | Allarity Therapeutics | 1.23 | ||||
| VRAX | Virax Biolabs | 2.34 | ||||
| PMVP | Pmv Pharmaceuticals | 2.84 | ||||
| BDRX | Biodexa Pharmaceticals | 3.48 | ||||
| KTTA | Pasithea Therapeutics | 4.92 | ||||
| QNRX | Quoin Pharmaceuticals | 13.89 |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.